Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$1.04M Sell
41,000
-431,100
-91% -$10.6M 0.07% 179
2025
Q2
$11.4M Buy
472,100
+397,100
+529% +$9.26M 0.43% 45
2025
Q1
$1.9M Sell
75,000
-5,000
-6% -$131K 0.08% 318
2024
Q4
$2.12M Sell
80,000
-134,000
-63% -$3.63M 0.08% 322
2024
Q3
$6.19M Sell
214,000
-256,700
-55% -$7.49M 0.21% 128
2024
Q2
$13.2M Buy
470,700
+283,800
+152% +$7.81M 0.47% 42
2024
Q1
$5.19M Buy
+186,900
New +$5.19M 0.16% 172

Other funds holding PFE

Point72 (DIFC)'s PFE Position: Q3 2024 in Review

Point72 (DIFC) sold out of Pfizer (PFE) in Q3 2024, closing a stake of 888,542 shares — an estimated $25.9M sold.

Point72 (DIFC) first reported a position in PFE in Q1 2024 and held it in 2 quarters. The position peaked at $24.9M in Q2 2024. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • Point72 (DIFC) reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 888,542 Pfizer shares in Q3 2024, an estimated $25.9M.
  • Point72 (DIFC) first reported a position in Pfizer in Q1 2024 and held it in 2 quarters.
  • Point72 (DIFC)'s Pfizer position peaked at $24.9M in Q2 2024.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Point72 (DIFC)'s 13F filing for Q3 2024, filed 14 Nov 2024.